AnaCardio raises €62.5 million in Series B led by Novo Holdings
Sound Bioventures, the Ljungström family office and Helsinn also invested. Proceeds will fund the GOAL-HF2 Phase 2b trial for AC01.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.